Reuters logo
7 months ago
BRIEF-FDA accepts for filing supplemental new drug application for Liletta
January 4, 2017 / 12:46 PM / 7 months ago

BRIEF-FDA accepts for filing supplemental new drug application for Liletta

Jan 4 (Reuters) - Allergan Plc :

* FDA accepts for filing supplemental new drug application (SNDA) for Liletta (levonorgestrel-releasing intrauterine system) 52 mg

* Allergan Plc - application seeks to extend duration of use up to 4 years for Liletta

* Allergan - FDA accepted co's SNDA to potentially extend duration of use for prevention of pregnancy from up to 3 yrs to up to 4 yrs for Liletta 52 mg Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below